Dashboard
Manage Tickers

AXGNAxogen, Inc.

Nasdaq axogeninc.com


$ 13.02 $ 0.00 (0 %)    

Monday, 09-Sep-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 13.02
$ 12.99 x 100
$ 13.02 x 190
-- - --
$ 3.45 - $ 13.35
366,136
na
570.66M
$ 1.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-05-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 10-30-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-24-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 10-29-2018 09-30-2018 10-Q
25 08-01-2018 06-30-2018 10-Q
26 04-30-2018 03-31-2018 10-Q
27 02-28-2018 12-31-2017 10-K
28 11-01-2017 09-30-2017 10-Q
29 08-02-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-01-2017 12-31-2016 10-K
32 11-02-2016 09-30-2016 10-Q
33 08-03-2016 06-30-2016 10-Q
34 05-04-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-05-2015 03-31-2015 10-Q
39 03-05-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

axogen-says-it-completed-submission-of-biologics-license-application-to-us-food-and-drug-administration-for-avance-nerve-graft
Axogen Says It Completed Submission Of Bio...
09/06/2024 11:10:29

cytosorbents-appoints-peter-j-mariani-as-chief-financial-officer-effective-august-14-2024-kathleen-p-bloch-retires-as-cfo-will-continue-as-consultant-to-ensure-smooth-transition
CytoSorbents Appoints Peter J. Mariani As ...
08/13/2024 20:41:20

jmp-securities-maintains-market-outperform-on-axogen-raises-price-target-to-20
JMP Securities Maintains Market Outperform...
08/09/2024 11:02:53

JMP Securities analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises the price target fro...

parker-hannifin-posts-upbeat-earnings-joins-under-armour-zillow-group-yeti-holdings-eli-lilly-and-other-big-stocks-moving-higher-on-thursday
Parker-Hannifin Posts Upbeat Earnings, Joi...
08/08/2024 15:09:43

axogen-expects-fy24-revenue-of-182m-186m-prior-177m-181m-vs-1789m-est
Axogen Expects FY24 Revenue Of $182M-$186M...
08/08/2024 11:09:58

2024 Financial Guidance We are increasing our annual revenue guidance to the range of $182 million to $186 million. We are als...

axogen-tapped-michael-dale-as-ceo-and-director-effective-august-9-taking-over-from-karen-zaderej
Axogen Tapped Michael Dale As CEO And Dire...
08/08/2024 11:06:38

Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve inju...

axogen-q2-2024-adj-eps-005-beats-004-estimate-sales-47912m-beat-43391m-estimate
Axogen Q2 2024 Adj. EPS $0.05 Beats $(0.04...
08/08/2024 11:01:17

raymond-james-initiates-coverage-on-axogen-with-outperform-rating-announces-price-target-of-13
Raymond James Initiates Coverage On Axogen...
07/01/2024 10:09:04

Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price...

axogen-launches-new-product-to-aid-nerve-healing-avive-soft-tissue-matrix
Axogen Launches New Product to Aid Nerve H...
06/24/2024 11:03:13

Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve inju...

canaccord-genuity-reiterates-buy-on-axogen-maintains-15-price-target
Canaccord Genuity Reiterates Buy on Axogen...
06/20/2024 16:10:39

Canaccord Genuity analyst Caitlin Cronin reiterates Axogen (NASDAQ:AXGN) with a Buy and maintains $15 price target.

axogen-initiates-rolling-submission-process-with-fda-for-biologics-license-application-for-licensure-of-avance-nerve-graft
Axogen Initiates Rolling Submission Proces...
05/16/2024 11:34:46

The company anticipates the BLA filing to be completed in the third quarter of 2024 and believe the procedural timelines for re...

axogen-reiterates-fy24-outlook-expects-revenues-to-grow-between-177m-181m-vs-17951m-estimate--which-represents-a-growth-rate-of-approximately-11-14
Axogen Reiterates FY24 Outlook: Expects Re...
05/02/2024 11:53:07

axogen-q1-2024-adj-eps-006-beats-007-estimate-sales-41378m-miss-41964m-estimate
Axogen Q1 2024 Adj EPS $(0.06) Beats $(0.0...
05/02/2024 11:18:26

Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14....

axogen-announces-first-surgical-implants-of-avive-soft-tissue-matrix
Axogen Announces First Surgical Implants o...
04/29/2024 20:51:27

why-sophia-genetics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why SOPHiA GENETICS Shares Are Trading Low...
03/05/2024 18:11:47

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...

axogen-expects-2024-revenue-of-177m-181m-up-11-14-versus-consensus-of-17922m-with-gross-margin-of-76-79
Axogen Expects 2024 Revenue Of $177M-$181M...
03/05/2024 12:12:01

axogen-q4-eps-006-beats-010-estimate-sales-4290m-beat-4165m-estimate
Axogen Q4 EPS $(0.06) Beats $(0.10) Estima...
03/05/2024 12:09:58

Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 40 ...

earnings-scheduled-for-march-5-2024
Earnings Scheduled For March 5, 2024
03/05/2024 10:00:02

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

axogen-earnings-preview
Axogen Earnings Preview
03/04/2024 15:01:29

cantor-fitzgerald-reiterates-overweight-on-axogen-maintains-12-price-target
Cantor Fitzgerald Reiterates Overweight on...
01/19/2024 14:24:57

Cantor Fitzgerald analyst Ross Osborn reiterates Axogen (NASDAQ:AXGN) with a Overweight and maintains $12 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION